Salvagene GROUP

Business Unit: SARS-CoV-2 Task Force
Keynote: #41

November 2020

The Salvagene Vaccine and Medication Advisory Board will be contacting our Premium clients with initial recommendations on vaccination against SARS-CoV-2 in approximately 4-6 weeks.

KEYNOTE

Dear Premium Customers,

Our Vaccine and Medication Advisory Board has been tracking up to 100 vaccine projects worldwide for several months now.

Right from the start, the project run by BioNTech in Mainz has ranked among the Top Three in our Salvagene Overall Success Index and, since summer, has taken over as the lead candidate ahead of AstraZeneca. As we have previously reported, there are four main technologies on the basis of which vaccines are developed, and the race between RNA and vector-based projects is particularly close. Indeed, these two technologies are clear leaders. BioNTech has long headed the list of RNA-based projects, with AstraZeneca as the main contender among the vector-based candidates. In the overall ranking, however, BioNTech still leads the way.

Furthermore, BioNTech has now pulled significantly ahead over the weekend with the publication of its vaccine success rates. We are familiar with the details of this project for two reasons: firstly, we enjoy excellent relations with Mainz-based BioNTech because

we have one of our own laboratories in the city; and secondly, because we both specialize in the field of cancer. Indeed, Salvagene started out in cancer prevention, while BioNTech's original area of expertise was in cancer therapy. Both companies make use of gene-based technologies, and in this respect, we have a clear understanding of what the BioNTech team does. And of course, contrary to the claims of the US administration, no information is withheld.

The reason for our positive evaluation is purely objective assessment. This project has been developed very much independently from government control or interference; for example, it is not part of the American or any other national vaccine initiative. The data that has been published has been produced without any political influence or input and is therefore highly credible. BioNTech has a global reach and, over and above the development and research work that has gone into the vaccine project, it also has a Chinese and American production partner, Pfizer, which ensures that this vaccine can be made available relatively quickly thanks to their high production capacities.

On our Salvagene Overall Success Index, RNA-based projects have a decisive advantage in that their vaccines can be produced in high doses relatively quickly. The potential drawback is that there has not been a single medication based on this technology to date, not even in cancer therapy. This makes a long-term assessment very difficult. We believe that epigenetic changes may occur in the long term, as a result of which side-effects may be either harmless or possibly more serious. We cannot rule such a complication out at this stage. The advantage is that, at least in the short term, all RNA-based projects have shown significantly fewer side-effects than vector-based projects. For example, AstraZeneca's leading vector-based technology project was repeatedly halted in Phase 3 due to possible side-effects. We assume that the side-effects in vector-based projects are of a more short-term nature, but are much more frequent, while

possible long-term side-effects are probably reduced in comparison with RNA-based projects.

Our Vaccine and Medication Advisory Board is now preparing to make individual recommendations for our Premium clients, starting in the next 4-6 weeks. We will base our recommendation for example on the vaccine projects available in the respective country, the client's overall health status, the functioning of the immune system, the areas to be optimized in the Premium Program, the age and the respective Pharmaco genetic profile.

Dependent in this your Salvagene Consultant will contact you at an early stage if there should be a vaccination against the SARS-CoV-2 virus recommendable as a significant supplement to your personal protection.

SALVAGENE HQ
Université Paris Sorbonne
125 Rue Saint-Jacques, 75005 Paris

SALVAGENE UK
52 Grosvenor Gardens • SW1W 0AU London UF
Tel: 0044 20 3287 0644

SALVAGENE USA
101 Avenue of the Americas, 8th floor • 10013 New York
Tel: +1 646 583 0370

info@salvagene.com • www.salvagene.com